DMKP.Q Stock Overview A clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
DMK Pharmaceuticals Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for DMK Pharmaceuticals Historical stock prices Current Share Price US$0.000001 52 Week High US$1.04 52 Week Low US$0.000001 Beta 1.35 1 Month Change -99.00% 3 Month Change 0% 1 Year Change -100.00% 3 Year Change -100.00% 5 Year Change -100.00% Change since IPO -100.00%
Recent News & Updates Second Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals Corporation Sep 10
Joint Liquidation Plan and Disclosure Statement Filed by DMK Pharmaceuticals Corporation Aug 03
First Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals Corporation Jun 15
Motion for Asset Sale Approved for DMK Pharmaceuticals Corporation May 09
Nasdaq to Delist Common Stock of DMK Pharmaceuticals Mar 22
DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Index Feb 08 See more updates Second Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals Corporation Sep 10
Joint Liquidation Plan and Disclosure Statement Filed by DMK Pharmaceuticals Corporation Aug 03
First Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals Corporation Jun 15
Motion for Asset Sale Approved for DMK Pharmaceuticals Corporation May 09
Nasdaq to Delist Common Stock of DMK Pharmaceuticals Mar 22
DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Index Feb 08
DMK Pharmaceuticals Corporation(OTCPK:DMKP.Q) dropped from NASDAQ Composite Index Feb 07
DMK Pharmaceuticals Corporation, Annual General Meeting, Jan 25, 2024 Jan 06
DMK Pharmaceuticals Corporation Regains Full Rights from US WorldMeds for SYMJEPI Nov 29
Adamis Pharmaceuticals Corporation(NasdaqCM:ADMP) dropped from NASDAQ Composite Index Nov 22
DMK Pharmaceuticals Corporation Receives a Superseding Notice from the Listing Qualifications Department of the Nasdaq Stock Market Oct 21 DMK Pharmaceuticals Corporation Announces CFO Changes
DMK Pharmaceuticals Corporation Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market Oct 18
DMK Pharmaceuticals Receives Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirements Oct 11
Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 09, 2023 Sep 02 Adamis Pharmaceuticals Corporation has completed a Composite Units Offering in the amount of $8.005387 million. Aug 06
Adamis Pharmaceuticals Corporation Announces Chief Financial Officer Changes
Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) acquired DMK Pharmaceuticals, Inc. from Windhover Ventures LLC. May 26 Adamis Pharmaceuticals Corporation Contemplates Bankruptcy
Adamis Pharmaceuticals Corporation to Report Q1, 2023 Results on May 15, 2023 May 09
Adamis Pharmaceuticals Corporation to Report Q3, 2022 Results on Nov 14, 2022 Nov 08 Adamis Pharmaceuticals Corporation Contemplates Bankruptcy Oct 05
Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure Sep 30
Adamis Pharmaceutics Corporation Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects Sep 23
Adamis Pharmaceuticals Corporation Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects Sep 13
Adamis Pharmaceuticals Corporation to Report Q2, 2022 Results on Aug 10, 2022 Aug 09
Adamis Pharmaceuticals Corporation Provides Update on Clinical Study Assessing Tempol for the Treatment of Covid-19 Jul 30
Next meeting of data safety board to review Adamis Pharma's COVID treatment in Sept. Jul 29
Adamis CEO urges stock split approval, slate of directors in letter to shareholders Jul 21 Adamis Pharmaceuticals Corporation announced that it has received $0.3 million in funding from Lincoln Park Capital, LLC
Adamis Pharmaceuticals Corporation Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19 Jun 02
Adamis Pharmaceuticals Corporation Appoints Vickie Reed to Board of Directors May 27 Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth Adamis Pharmaceuticals Corporation to Report Q1, 2022 Results on May 16, 2022
Adamis Pharmaceuticals: Preparing For Another Round Of Success, Failure, Then Hope Apr 13 Adamis Pharmaceuticals Corporation Contemplates Bankruptcy
Richard C. Williams Notifies Adamis Pharmaceuticals Corporation That Effective April 15, 2022, He Will Be Retiring Mar 06
Adamis Pharmaceuticals Corporation’S Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations Mar 01
Adamis Pharmaceuticals Corporation Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19 Feb 08
Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic Jan 20
Adamis Pharmaceuticals Corporation Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19 Jan 12
Adamis Pharmaceuticals Receives A Notice from the Listing Qualifications Department of the Nasdaq Stock Market Jan 07
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 Mg Intramuscular Dose of Naloxone in Zimhi™ Dec 02
Adamis Pharmaceuticals: It's Now Or Never Dec 02
Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements Nov 24
Adamis Pharmaceuticals: TEMPOL's Near-Term And Long-Term Upside Improves As Variants Sidestep Vaccines Sep 03
Adamis Pharmaceuticals Corporation Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19 Sep 03
Adamis Pharmaceuticals Receives A Notification Letter from the Listing Qualifications Department of the Nasdaq Stock Market Aug 26
Adamis Pharmaceuticals Corporation announced delayed 10-Q filing Aug 17
An unknown buyer completed the acquisition of U.S. Compounding, Inc. from Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) for $15 million. Aug 06
Adamis Pharmaceuticals: Potential COVID Drug Could Reignite Shares Jun 13
Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19 Jun 12
Adamis Provides Update on ZIMHI™ Jun 10
Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19 Jun 08
Adamis Pharma gains 9% after Tempol shows potential as an antiviral drug for COVID-19 Jun 07
Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ May 29
Adamis pharmaceuticals gets deficiency letter from NASDAQ May 28
Adamis Pharmaceuticals Corporation announced delayed amended 10-Q filing May 25 Adamis Pharmaceuticals Corporation announced delayed 10-Q filing
Adamis Pharmaceuticals Corporation announced delayed annual 10-K filing Apr 02
Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the Covid-19 Challenged Hamster Model Mar 17
Adamis Pharmaceuticals Corporation Clears to Proceed with Human Studies of Tempol for the Treatment of COVID-19 Feb 24
Adamis Pharmaceuticals Strengthens Patent Portfolio for its Naloxone Product Candidate Feb 18
Adamis Pharmaceuticals Corporation has completed a Follow-on Equity Offering in the amount of $44.999999 million. Jan 31
Adamis Pharmaceuticals (ADMP) trades sharply lower after pricing public offering Jan 29 Adamis Pharmaceuticals Corporation Announces the Availability of SYMJEPI Products in the Walgreens Prescription Savings Club
Adamis Pharmaceuticals Receives Complete Response Letter from the FDA Regarding ZIMHI Nov 17
Adamis Pharma plunges 43% on FDA rejection of Zimhi application for opioid overdose Nov 16
Adamis Pharmaceuticals EPS misses by $0.01, misses on revenue Nov 09 Shareholder Returns DMKP.Q US Pharmaceuticals US Market 7D 0% -0.6% -0.2% 1Y -100.0% 3.0% 25.6%
See full shareholder returns
Return vs Market: DMKP.Q underperformed the US Market which returned 30.3% over the past year.
Price Volatility Is DMKP.Q's price volatile compared to industry and market? DMKP.Q volatility DMKP.Q Average Weekly Movement 466,513.1% Pharmaceuticals Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.1%
Stable Share Price: DMKP.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DMKP.Q's weekly volatility has increased from 198704% to 466513% over the past year.
About the Company DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company’s lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose.
Show more DMK Pharmaceuticals Corporation Fundamentals Summary How do DMK Pharmaceuticals's earnings and revenue compare to its market cap? DMKP.Q fundamental statistics Market cap US$10.00 Earnings (TTM ) -US$21.33m Revenue (TTM ) US$3.62m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) DMKP.Q income statement (TTM ) Revenue US$3.62m Cost of Revenue US$4.97m Gross Profit -US$1.35m Other Expenses US$19.98m Earnings -US$21.33m
Last Reported Earnings
Sep 30, 2023
Earnings per share (EPS) -2.11 Gross Margin -37.30% Net Profit Margin -589.28% Debt/Equity Ratio 0%
How did DMKP.Q perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/11/21 07:12 End of Day Share Price 2024/11/19 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources DMK Pharmaceuticals Corporation is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Andrew D'Silva B. Riley Securities, Inc. Timothy Chiang CRT Capital Group Jason Kolbert H.C. Wainwright & Co.
Show 3 more analysts 
